Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyureaAlberto Álvarez‐Larrán, Beatríz Bellosillo, Eduardo Arellano‐Rodrigo et al.|Cancer|2022Cited by 32
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of MyelofibrosisAdrián Mosquera-Orgueira, Manuel Pérez‐Encinas, Alberto Hernández‐Sánchez et al.|HemaSphere|2022Cited by 30
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of MyelofibrosisJuan Carlos Hernández‐Boluda, Irene Pastor‐Galán, Eduardo Arellano‐Rodrigo et al.|British Journal of Haematology|2022Cited by 16
The prognostic impact of non‐driver gene mutations and variant allele frequency in primary myelofibrosisAlberto Hernández‐Sánchez, Á. Villaverde-Ramiro, Eduardo Arellano‐Rodrigo et al.|American Journal of Hematology|2024Cited by 8
Integrating AIPSS‐MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosisAdrián Mosquera Orgueira, Eduardo Arellano‐Rodrigo, Marta Garrote et al.|HemaSphere|2024Cited by 6